BR112018071363A2 - composições farmacêuticas orais de nicotinamida - Google Patents
composições farmacêuticas orais de nicotinamidaInfo
- Publication number
- BR112018071363A2 BR112018071363A2 BR112018071363A BR112018071363A BR112018071363A2 BR 112018071363 A2 BR112018071363 A2 BR 112018071363A2 BR 112018071363 A BR112018071363 A BR 112018071363A BR 112018071363 A BR112018071363 A BR 112018071363A BR 112018071363 A2 BR112018071363 A2 BR 112018071363A2
- Authority
- BR
- Brazil
- Prior art keywords
- nicotinamide
- pharmaceutical compositions
- oral
- oral nicotinamide
- mesalazine
- Prior art date
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title abstract 8
- 229960003966 nicotinamide Drugs 0.000 title abstract 4
- 235000005152 nicotinamide Nutrition 0.000 title abstract 4
- 239000011570 nicotinamide Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 abstract 2
- 229960004963 mesalazine Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324415P | 2016-04-19 | 2016-04-19 | |
| PCT/US2017/028063 WO2017184563A1 (en) | 2016-04-19 | 2017-04-18 | Oral pharmaceutical compositions of nicotinamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018071363A2 true BR112018071363A2 (pt) | 2019-02-05 |
Family
ID=59227843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018071363A BR112018071363A2 (pt) | 2016-04-19 | 2017-04-18 | composições farmacêuticas orais de nicotinamida |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11622938B2 (https=) |
| EP (1) | EP3445360B1 (https=) |
| JP (1) | JP7021108B2 (https=) |
| KR (1) | KR20180135020A (https=) |
| CN (1) | CN109152772B (https=) |
| AR (1) | AR108233A1 (https=) |
| AU (1) | AU2017252407A1 (https=) |
| BR (1) | BR112018071363A2 (https=) |
| CA (1) | CA3021066C (https=) |
| ES (1) | ES2848575T3 (https=) |
| RU (1) | RU2738114C2 (https=) |
| TW (1) | TW201739455A (https=) |
| WO (1) | WO2017184563A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2861229T3 (da) | 2012-06-15 | 2021-01-18 | Conaris Res Institute Ag | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen |
| WO2015086838A2 (en) | 2013-12-13 | 2015-06-18 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| HUE048488T2 (hu) | 2013-12-13 | 2020-07-28 | Conaris Res Institute Ag | Nikotinsavat és/vagy nikotinamidot tartalmazó gyógyászati készítmény a vérlipid szint jótékony hatású befolyására történõ alkalmazásra a bélrendszeri mikrobióta módosításával |
| US20210236519A1 (en) * | 2020-01-30 | 2021-08-05 | Atoz Pharmaceuticals Pvt Ltd | Controlled release dosage forms of 5-aminosalicylic acid and process thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791458A (fr) | 1972-07-31 | 1973-05-16 | Merck & Co Inc | Produit microencapsule |
| IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| JP3455544B2 (ja) | 1994-06-02 | 2003-10-14 | リガ ダン | 抗ストレス剤、抗機能障害剤および抗老化剤、ならびに該薬剤の製造法 |
| WO1998022096A1 (en) * | 1996-11-15 | 1998-05-28 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
| GB0007419D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
| IT1318625B1 (it) | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
| US6897205B2 (en) * | 2001-01-31 | 2005-05-24 | Roehm Gmbh & Co. Kg | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
| US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| MX2007008833A (es) * | 2005-01-21 | 2008-03-25 | Pharmanova Inc | Formulaciones farmaceuticas y metodos de uso. |
| EP1935422A1 (en) | 2006-12-20 | 2008-06-25 | PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG | Pharmaceutical composition comprising nicotinamide or nicotinic acid |
| US20080286344A1 (en) | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
| US20110104282A1 (en) | 2008-04-25 | 2011-05-05 | Karolinska Institutet Innovations Ab | New Therapy of Treatment of the Irritable Bowel Syndrome |
| WO2010010579A1 (en) | 2008-07-19 | 2010-01-28 | Lupin Limited | Multiple unit dosage form of niacin |
| EP2367421A4 (en) | 2008-12-17 | 2013-03-13 | Altheus Therapeutics Inc | ORAL FORMULAS |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| GB201003731D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| GB201003734D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| EP2468264A1 (en) | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| AU2013229990B2 (en) | 2012-03-07 | 2017-07-06 | Santarus, Inc. | Controlled-release solid dosage forms of mesalamine |
| US20150164920A1 (en) | 2012-03-30 | 2015-06-18 | Laboratorios Del Dr. Esteve S.A. | Controlled release formulation comprising mesalamine |
| DK2861229T3 (da) | 2012-06-15 | 2021-01-18 | Conaris Res Institute Ag | Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen |
| US20140178468A1 (en) | 2012-12-24 | 2014-06-26 | Ranbaxy Laboratories Limited | Multiparticulate extended-release composition of mesalamine |
| US9763887B2 (en) | 2013-03-15 | 2017-09-19 | Allergan Pharmaceuticals International Limited | Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability |
| US10456389B2 (en) | 2013-06-14 | 2019-10-29 | Conaris Research Institute Ag | Extended release nicotinamide formulation |
| HUE048488T2 (hu) * | 2013-12-13 | 2020-07-28 | Conaris Res Institute Ag | Nikotinsavat és/vagy nikotinamidot tartalmazó gyógyászati készítmény a vérlipid szint jótékony hatású befolyására történõ alkalmazásra a bélrendszeri mikrobióta módosításával |
| WO2015086838A2 (en) * | 2013-12-13 | 2015-06-18 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| EP3154523B1 (en) | 2014-06-16 | 2018-11-21 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
| US20160045442A1 (en) | 2014-08-13 | 2016-02-18 | Cadila Healthcare Limited | Stable pharmaceutical compositions of mesalamine |
| CN104257669A (zh) | 2014-09-25 | 2015-01-07 | 合肥平光制药有限公司 | 一种用于向肠道递送水杨酸类药物的口服给药组合物 |
| BR112018071370A2 (pt) | 2016-04-19 | 2019-02-05 | Ferring Bv | composições farmacêuticas orais de mesalazina |
-
2017
- 2017-04-18 TW TW106112905A patent/TW201739455A/zh unknown
- 2017-04-18 AU AU2017252407A patent/AU2017252407A1/en not_active Abandoned
- 2017-04-18 BR BR112018071363A patent/BR112018071363A2/pt not_active Application Discontinuation
- 2017-04-18 AR ARP170100995A patent/AR108233A1/es unknown
- 2017-04-18 US US16/094,654 patent/US11622938B2/en active Active
- 2017-04-18 CN CN201780029815.4A patent/CN109152772B/zh active Active
- 2017-04-18 RU RU2018137323A patent/RU2738114C2/ru active
- 2017-04-18 EP EP17733604.7A patent/EP3445360B1/en active Active
- 2017-04-18 CA CA3021066A patent/CA3021066C/en active Active
- 2017-04-18 JP JP2018554492A patent/JP7021108B2/ja active Active
- 2017-04-18 WO PCT/US2017/028063 patent/WO2017184563A1/en not_active Ceased
- 2017-04-18 ES ES17733604T patent/ES2848575T3/es active Active
- 2017-04-18 KR KR1020187033390A patent/KR20180135020A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TW201739455A (zh) | 2017-11-16 |
| CN109152772A (zh) | 2019-01-04 |
| JP2019513801A (ja) | 2019-05-30 |
| JP7021108B2 (ja) | 2022-02-16 |
| RU2018137323A3 (https=) | 2020-07-13 |
| US20200155461A1 (en) | 2020-05-21 |
| CA3021066A1 (en) | 2017-10-26 |
| KR20180135020A (ko) | 2018-12-19 |
| EP3445360B1 (en) | 2020-11-11 |
| RU2018137323A (ru) | 2020-05-19 |
| EP3445360A1 (en) | 2019-02-27 |
| US11622938B2 (en) | 2023-04-11 |
| RU2738114C2 (ru) | 2020-12-08 |
| AR108233A1 (es) | 2018-08-01 |
| WO2017184563A1 (en) | 2017-10-26 |
| AU2017252407A1 (en) | 2018-11-01 |
| CN109152772B (zh) | 2021-09-28 |
| ES2848575T3 (es) | 2021-08-10 |
| CA3021066C (en) | 2024-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123361T1 (el) | Παραγωγο ισοϊνδολινης, ενδιαμεσο, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτου | |
| CY1125772T1 (el) | Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| MX386752B (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| IL264065A (en) | Oral gastroretentive formulations and uses thes thereof | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| MX387235B (es) | Derivados de pirazolopiridina y su uso en terapia | |
| BR112018071370A2 (pt) | composições farmacêuticas orais de mesalazina | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
| UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
| CY1122473T1 (el) | Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης | |
| BR112017009510A2 (pt) | composições compreendendo ciclosporina | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| NI201600091A (es) | UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS | |
| BR112018071363A2 (pt) | composições farmacêuticas orais de nicotinamida | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| PH12018501758A1 (en) | Oritavancin formulations | |
| MX381148B (es) | Polipéptidos de acción prolongada y métodos para su producción y administración. | |
| MX393915B (es) | Nuevas formulaciones orales de belinostat. | |
| BR112017009848A2 (pt) | combinação, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica. | |
| CY1122708T1 (el) | Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |